Skye Bioscience Class Action Lawsuit: 8 Frequently Asked Questions

• Skye Bioscience Class Action Lawsuit: The Skye Bioscience class action lawsuit seeks to represent purchasers or acquirers of Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024, and October 3, 2025, inclusive (the “Class Period”).  Captioned Stout v. Skye Bioscience, Inc., No. 25-cv-03177 (S.D. Cal.), the Skye Bioscience class action lawsuit charges Skye Bioscience and certain of Skye Bioscience’s top executives with violations of the Securities Exchange Act of 1934..
• Contact Timothy L. Miles: If you suffered substantial losses and wish to serve as lead plaintiff of the Skye Bioscience class action lawsuit, or just have general questions about your rights as a shareholder, please contact attorney Timothy L. Miles or at 855-846-6529 or via e-mail at [email protected].

• Deadline to Lead: The deadline to apply to be Lead Plaintiff is January 16, 2026.

1. Who Is Affected by the Skye Bioscience class action lawsuit?

Purchasers or acquirers of Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024, and October 3, 2025, inclusive (the “Class Period”).

2. How Does it Work?

• A lawsuit is initiated by one or more investors, called the “lead plaintiffs,” on behalf of a larger group of investors, or the “class”.

• The “class period” is defined as the specific timeframe during which the alleged fraudulent activity took place. Only those who bought or sold the security during this period are eligible to participate.

• A lead plaintiff is appointed to represent the class. Under the Private Securities Litigation Reform Act (PSLRA), the court will typically appoint the investor with the largest financial interest in the outcome of the case.

• The case is litigated, which may include a lengthy discovery phase for gathering evidence.

• The case can be settled or go to trial. Most class actions are resolved through settlements, which can include cash or stock paid into a common fund for the class. The lead plaintiff and class counsel approve any settlement before it is finalized.

3. What Do the Plaintiffs Have to Prove in the Skye Bioscience class action lawsuit?

To succeed in a federal securities fraud class action, plaintiffs must prove several elements:

• Material misstatement or omission: The company made a false or misleading statement or failed to disclose a material fact.

• Scienter: The defendant acted with an intent to deceive, manipulate, or defraud.

• Reliance: The plaintiff relied on the misstatement or omission when buying or selling the security. For publicly traded securities, this can be proven through the “fraud-on-the-market” theory, which presumes the market price reflects all public, material information.

• Economic loss: The plaintiff suffered a financial loss.

• Loss causation: The company’s misstatement or omission directly caused the plaintiff’s loss, often demonstrated by a stock price drop after the truth is revealed in a “corrective disclosure”

4. What Are the Benefits for Investors in Joining the Skye Bioscience class action lawsuit?

• Participating in a class action allows investors to pool their resources, which offers leverage they would not have in an individual lawsuit against a large corporation.

• The collective approach also makes it more efficient and cost-effective to pursue legal action, especially for smaller investors.

5. How Do I Get Involved in the Skye Bioscience class action lawsuit?

• If you bought a security during the alleged class period and suffered a loss, you are generally automatically included in the class. You don’t have to take any action unless you want to file a claim for recovery later.

• You may be notified of a class action by mail if you are an eligible class member.

• You may be able to become a lead plaintiff by applying within 60 days of the first lawsuit being announced.

• If you believe you may have a claim, you can contact a securities class action law firm for guidance. 

6. What Are the Allegations in the Skye Bioscience class action lawsuit?

Overview

• Skye Bioscience: is a clinical stage biopharmaceutical company that focuses on developing molecules to treat obesity, overweight, and metabolic diseases.

• According to the Complaint: In August 2024, Skye Bioscience initiated its “CBeyond” clinical trial, a twenty-six-week, randomized, double-blind, placebo-controlled Phase 2a proof-of-concept study designed to assess Skye Bioscience’s nimacimab product candidate as a treatment for obesity and overweight.

False and Misleading Statements

The Skye Bioscience class action lawsuit alleges that throughout the Class Period defendants made false and/or misleading statement and/or failed to disclose that:

• (i)  Nimacimab was less effective than defendants had led investors to believe; and

• (ii) Accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated.

October 6, 2025, Announcement

• The Skye Bioscience Class Action Lawsuit: Alleges that on October 6, 2025, Skye Bioscience announced topline data from the CBeyond clinical trial, disclosing that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.”

• On this News: The price of Skye Bioscience stock fell 60%, according to the complaint.

7. When is the Lead Plaintiff Deadline in the Skye Bioscience Class Action Lawsuit?

• Lead Plaintiff Deadline: Lead plaintiff motions in the Skye Bioscience class action lawsuit must be filed with the court no later than January 16, 2026

8. What Are the Eligibility Criteria for Lead Plaintiff Appointment in the Skye Bioscience Lawsuit?

To be eligible for appointment as the lead plaintiff in the Skye Bioscience class action lawsuit, an investor must meet the following criteria:

• Securities Acquisition: The investor must have purchases or acquired of Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024, and October 3, 2025, inclusive (the “Class Period”).

• Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by Skye Bioscience and its executives.

• Typicality and Adequacy: The investor’s legal claims must be typical of those asserted on behalf of the class, and they must demonstrate their ability to adequately represent the interests of the entire class through experience, resources, and the absence of conflicts of interest.

It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the class action lawsuit, as courts have consistently recognized the rights of non-U.S. investors in securities class actions.